Citius Pharmaceuticals, Inc. - Common Stock (CTXR)
1.9150
+1.0650 (125.29%)
NASDAQ · Last Trade: Jun 9th, 1:00 PM EDT
Detailed Quote
Previous Close
0.8500
Open
0.9100
Bid
1.910
Ask
1.920
Day's Range
0.8900 - 2.380
52 Week Range
0.6500 - 26.25
Volume
65,698,944
Market Cap
279.55M
PE Ratio (TTM)
-0.3330
EPS (TTM)
-5.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
153,858
Chart
About Citius Pharmaceuticals, Inc. - Common Stock (CTXR)
Citius Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapeutic products for critical care and cancer treatment. The company primarily specializes in the formulation and commercialization of medical products that aim to address unmet medical needs in the areas of oncology and critical care medicine. Citius is actively engaged in advancing its product pipeline through clinical trials, emphasizing the development of safe and effective therapies to improve patient outcomes. The company's commitment to research and development positions it as a key player in the pharmaceutical landscape, aiming to provide new treatment options for healthcare providers and patients alike. Read More
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Citius Pharmaceuticals receives FDA approval for Lymphir, the first therapy targeting the IL-2 receptor in relapsed or refractory cutaneous T-cell lymphoma. U.S. market launch planned within five months.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com, a go-to investing platform releases the second...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 17, 2024) - Investorideas.com, a go-to investing platform releases the first...
Investing in the pharmaceutical industry carries inherent risks, especially when it involves pre-commercial entities where the outcome hinges on the unpredictable reactions of chemicals within the human body and the critical approval of regulators. However, a distinct stage in the regulatory process progressively “de-risks” these investments. As drugs transition through Phase I, Phase II, and Phase III to NDA/BLA submissions, their likelihood of reaching commercialization, generating revenue, and turning a profit increases substantially.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second...
